WHO Endorses GLP-1 Drugs for Obesity: A New Era in Global Health

The World Health Organization has issued its first guideline recommending GLP-1 therapies for long-term obesity treatment. As demand for these drugs surges globally, WHO emphasizes the need for equitable access, highlighting concerns about affordability and health system capacity to manage widespread delivery.

The World Health Organization issued its first guideline recommending GLP-1 therapies for long-term obesity treatment, affecting over 1 billion people worldwide. The announcement suggests using GLP-1 agonists, except for pregnant women, alongside healthy diet and physical activity as part of a holistic approach to treating obesity.

While acknowledging the potential of these drugs to tackle obesity, WHO Director-General Tedros Adhanom Ghebreyesus warned that medication alone won't solve the crisis, stressing the necessity for comprehensive care. Dr. Marie Spreckley highlighted the uncertainties regarding the long-term use, affordability, and the capacity of health systems to accommodate these drugs effectively.

The guiding principle behind the recommendation underscores equitable access, as current projections estimate the therapies will only reach under 10% of potential beneficiaries by 2030. The WHO calls for improved production, affordability, and procurement strategies, drawing parallels with successful programs like HIV treatment, to ensure these life-changing drugs bridge rather than deepen the existing health divide.

(With inputs from agencies.)